At what enterprise value was KARO HEALTHCARE acquired in 2025?

During the acquisition of KARO HEALTHCARE by KKR in 2025, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Retail & Consumer industry currently tracks an average EBITDA multiple of 11.3x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of KARO HEALTHCARE when it was acquired by KKR?

The estimated EV/EBITDA multiple for KARO HEALTHCARE is in the range of 15x - 25x. For comparison, the Retail & Consumer sector currently shows an average EBITDA multiple of 11.3x. Join our community for free to access full valuation data and industry trends.

When was KARO HEALTHCARE acquired by KKR?

KARO HEALTHCARE was acquired by KKR in 2025.

What was the revenue of KARO HEALTHCARE at the time of the deal?

The revenue of KARO HEALTHCARE at the time of the deal is estimated to be in the range of 450M - 900M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of KARO HEALTHCARE during the acquisition?

KARO HEALTHCARE's EBITDA is estimated to be in the range of 100M - 200M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the KARO HEALTHCARE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the KARO HEALTHCARE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.karohealthcare.com/karo-healthcare-announces-kkr-as-new-owner-following-successful-strategic-transformation-into-pan-european-consumer-healthcare-player/

← DATABASE

Home Database Retail & ConsumerKARO HEALTHCARE

08/2025

KARO HEALTHCARE

Acquired by

KKR

SWEDEN Consumer Products / Personal & Household / Hygiene & Beauty Brands EV 1b - 4b EUR

KARO HEALTHCARE acquired by KKR

SWEDEN Consumer Products / Personal & Household / Hygiene & Beauty Brands EV 1b - 4b EUR

Context

KKR has finalized the 100% acquisition of Karo Healthcare from the EQT VIII fund in a transaction initially announced in April 2025. The strategic rationale for KKR is to capitalize on a pan-European platform already structured for significant scale. Following a period where revenues quadrupled under EQT, Karo is entering an international acceleration phase. KKR plans to leverage its global footprint to deepen Karo’s reach across new distribution channels and geographies, while continuing to consolidate the fragmented sector through targeted bolt-on acquisitions. The transaction was advised by Citigroup and J.P. Morgan for KKR, and Morgan Stanley and Jefferies for EQT.

KARO HEALTHCARE, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Retail & Consumer sector (11.3x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Retail & Consumer market trends

Target

Karo Healthcare is a leading European platform specialized in over-the-counter (OTC) consumer healthcare products. Under EQT's ownership, the company underwent a radical transformation, evolving from a Nordic specialty pharma player into a pan-European champion. Its portfolio focuses on trusted brands in resilient categories: Skin Health, Foot Health, Intimate Health, Digestive Health, and Vitamins, Minerals & Supplements (VMS). Present in over 90 countries, Karo relies on a highly digitized commercial platform and a mixed growth model combining organic performance with an aggressive "Buy-and-Build" strategy, evidenced by eight acquisitions completed since 2019.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Other operations with KARO HEALTHCARE

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 450M - 900M EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of KARO HEALTHCARE by KKR are reserved for mynth community members. Register for free to unlock full data.

Authors: mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: kkr